Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Omega-3 Supplementation and Outcomes of Heart Failure: A Systematic Review of Clinical Trials Publisher Pubmed



Nomali M1 ; Heidari ME2 ; Ayati A3 ; Tayebi A4 ; Shevchuk O5 ; Mohammadrezaei R6 ; Navid H7 ; Khayyatzadeh SS8, 9 ; Palii S10 ; Valizade Shiran F11 ; Khorasanian AS12 ; Veysi Z13 ; Jamalzehi A14 ; Lesani A15 Show All Authors
Authors
  1. Nomali M1
  2. Heidari ME2
  3. Ayati A3
  4. Tayebi A4
  5. Shevchuk O5
  6. Mohammadrezaei R6
  7. Navid H7
  8. Khayyatzadeh SS8, 9
  9. Palii S10
  10. Valizade Shiran F11
  11. Khorasanian AS12
  12. Veysi Z13
  13. Jamalzehi A14
  14. Lesani A15
  15. Assari G16
  16. Khani S17
  17. Hassanpour K18
  18. Gerami H8, 19

Source: Medicine (United States) Published:2024


Abstract

Backgrounds: Omega-3 supplements are endorsed for heart failure (HF) patients to reduce hospitalizations and mortality, offering anti-inflammatory and cardioprotective benefits. Methods: A comprehensive search was conducted in various databases until November 2022. Eligible studies included clinical trials on patients with HF. Data extraction covered study details, omega-3 specifics, outcomes, and limitations. The JADAD scale was used to assess the risk of bias in randomized controlled trials. Results: The review process involved 572 records from database searches, resulting in 19 studies after eliminating duplicates and screening. These studies assessed the impact of omega-3 on various clinical outcomes, such as mortality, hospitalization, cardiac function, and quality of life. Studied duration varied from weeks to years. Omega-3 supplementation demonstrated potential benefits such as improved heart function, reduced inflammation, and decreased risk of cardiovascular events. Conclusion: Omega-3 supplementation could benefit heart disease treatment, potentially reducing therapy duration and improving outcomes. Starting omega-3 supplementation for HF patients seems favorable. © 2024 Lippincott Williams and Wilkins. All rights reserved.
Other Related Docs